bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure S1 from Cotargeting of Epidermal Growth Factor Receptor and PI3K Overcomes PI3K–Akt Oncogenic Dependence in Pancreatic Ductal Adenocarcinoma
Authors: Wong Matthew H. , Xue Aiqun , Julovi Sohel M. , Pavlakis Nick , Samra Jaswinder S. , Hugh Thomas J. , Gill Anthony J. , Peters Lyndsay , Baxter Robert C. , Smith Ross C.
Published: April 2023

Figure S1: EGFR and PI3K signaling in 5 PDAC cell lines. (A) Densitometric quantitation of Western blotting of pAkt/ total Akt (left panel) and pERK/ total ERK (right panel), with no treatment (NT), or stimulation by EGF, IGF-1, or both growth factors: average ï‚± SEM of 3 experiments. (B) Quantitation of Western blot of pEGFR, pIGF1R, pERK and pAkt in response to increasing dose of erlotinib or NVP-AEW541, average of 3 experiments. Drug doses were selected based on relative potency from proliferation assay and investigator brochure. Note that all signals were adjusted to EGF-stimulated control, so for PANC-1 which had a much more highly EGF-stimulated pAkt, the relative fold-change with erlotinib inhibition appeared smaller than for BxPC-3. * P<0.05, ** P<0.01
Supplementary Figure 6 from Epigenetics Markers of Metastasis and HPV-Induced Tumorigenesis in Penile Cancer
Authors: Feber Andrew , Arya Manit , de Winter Patricia , Saqib Muhammad , Nigam Raj , Malone Peter R. , Tan Wei Shen , Rodney Simon , Lechner Matthias , Freeman Alex , Jameson Charles , Muneer Asif , Beck Stephan , Kelly John D.
Published: April 2023

Supplementary Figure 6. Heatmap of 6 HNSCC cell lines (in duplicate) showing the methylation of the 30 probe set HPV classifier
Supplementary Figure 5 from Epigenetics Markers of Metastasis and HPV-Induced Tumorigenesis in Penile Cancer
Authors: Feber Andrew , Arya Manit , de Winter Patricia , Saqib Muhammad , Nigam Raj , Malone Peter R. , Tan Wei Shen , Rodney Simon , Lechner Matthias , Freeman Alex , Jameson Charles , Muneer Asif , Beck Stephan , Kelly John D.
Published: April 2023

Supplementary Figure 5. A) Receiver Operator Curve (ROC), for the accuracy of the epigenetic lymph node prediction signature in cross validation. B) Examples of FLI1 and IRX4 immunohistochemical staining of a PeCa TMA, in samples showing either methylation.
Supplementary Figure 4 from Epigenetics Markers of Metastasis and HPV-Induced Tumorigenesis in Penile Cancer
Authors: Feber Andrew , Arya Manit , de Winter Patricia , Saqib Muhammad , Nigam Raj , Malone Peter R. , Tan Wei Shen , Rodney Simon , Lechner Matthias , Freeman Alex , Jameson Charles , Muneer Asif , Beck Stephan , Kelly John D.
Published: April 2023

Supplementary Figure 4. Comparison of DMR profiles across canonical features for PeCa (green) and normal squamous epithelium (red), for three candidate epigenetically regulated genes involved in the development of penile cancer (AR &CDO1).
Supplemental Data Legends from A Novel MAPK–microRNA Signature Is Predictive of Hormone-Therapy Resistance and Poor Outcome in ER-Positive Breast Cancer
Authors: Miller Philip C. , Clarke Jennifer , Koru-Sengul Tulay , Brinkman Joeli , El-Ashry Dorraya
Published: April 2023

Supplemental Data Legends. Figure and table legends for supplemental data
Supplementary Figure 3 from Epigenetics Markers of Metastasis and HPV-Induced Tumorigenesis in Penile Cancer
Authors: Feber Andrew , Arya Manit , de Winter Patricia , Saqib Muhammad , Nigam Raj , Malone Peter R. , Tan Wei Shen , Rodney Simon , Lechner Matthias , Freeman Alex , Jameson Charles , Muneer Asif , Beck Stephan , Kelly John D.
Published: April 2023

Supplementary Figure 3. Methylation profiles of PeCa (green) and normal penile tissue (red) across canonical gene structure
Supplementary Table 5 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer In Vivo
Authors: Li Chong , Yang Zhao , Du Ying , Tang Haidong , Chen Jun , Hu Deqing , Fan Zusen
Published: April 2023

GALNT1 is highly expressed in the bladder cancer among all the N-acetylgalactosaminyltransferases.
Supplementary Table 4 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer In Vivo
Authors: Li Chong , Yang Zhao , Du Ying , Tang Haidong , Chen Jun , Hu Deqing , Fan Zusen
Published: April 2023

Complete information of the detected glycans by glycochip assay.
Supplementary Figures 1-6 from Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor–Initiating Cells
Authors: Venugopal Chitra , Hallett Robin , Vora Parvez , Manoranjan Branavan , Mahendram Sujeivan , Qazi Maleeha A. , McFarlane Nicole , Subapanditha Minomi , Nolte Sara M. , Singh Mohini , Bakhshinyan David , Garg Neha , Vijayakumar Thusyanth , Lach Boleslaw , Provias John P. , Reddy Kesava , Murty Naresh K. , Doble Bradley W. , Bhatia Mickie , Hassell John A. , Singh Sheila K.
Published: April 2023

Supplementary Figures 1-6. Supplementary Figure 1: CD133 correlates patient outcome with GIC selfrenewal and proliferative capacities in human GBM; Supplementary Figure 2: Gene Set Enrichment Analysis (GSEA) results for embryonic stem cell gene sets in CD133high- and CD133low-signature REMBRANDT samples; Supplementary Figure 3: CD133+ GICs are resistant to most compounds selected from CD133 connectivity mapping; Supplementary Figure 4: Pyrvinium specifically targets CD133+ GICs; Supplementary Figure 5: Overexpression of CD133; Supplementary Figure 6: Gene Set Enrichment Analysis (GSEA) results of Pyrvinium or DMSO control treated GICs
Supplementary Table 2 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer In Vivo
Authors: Li Chong , Yang Zhao , Du Ying , Tang Haidong , Chen Jun , Hu Deqing , Fan Zusen
Published: April 2023

Relationship between expression levels of the BCMab1 epitope and clinicopathological features of human bladder cancers.
Table S4 from MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer
Authors: García-García Celina , Rivas Martín A. , Ibrahim Yasir H. , Calvo María Teresa , Gris-Oliver Albert , Rodríguez Olga , Grueso Judit , Antón Pilar , Guzmán Marta , Aura Claudia , Nuciforo Paolo , Jessen Katti , Argilés Guillem , Dienstmann Rodrigo , Bertotti Andrea , Trusolino Livio , Matito Judit , Vivancos Ana , Chicote Irene , Palmer Héctor G. , Tabernero Josep , Scaltriti Maurizio , Baselga José , Serra Violeta
Published: April 2023

Table S4. Molecular characteristics of colorectal cancer PDX (IRCC panel)
Table S2 from MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer
Authors: García-García Celina , Rivas Martín A. , Ibrahim Yasir H. , Calvo María Teresa , Gris-Oliver Albert , Rodríguez Olga , Grueso Judit , Antón Pilar , Guzmán Marta , Aura Claudia , Nuciforo Paolo , Jessen Katti , Argilés Guillem , Dienstmann Rodrigo , Bertotti Andrea , Trusolino Livio , Matito Judit , Vivancos Ana , Chicote Irene , Palmer Héctor G. , Tabernero Josep , Scaltriti Maurizio , Baselga José , Serra Violeta
Published: April 2023

Table S2. Primer pairs for the relevant actionable genes in this study
Supplementary Figure and Table Legends from MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer
Authors: García-García Celina , Rivas Martín A. , Ibrahim Yasir H. , Calvo María Teresa , Gris-Oliver Albert , Rodríguez Olga , Grueso Judit , Antón Pilar , Guzmán Marta , Aura Claudia , Nuciforo Paolo , Jessen Katti , Argilés Guillem , Dienstmann Rodrigo , Bertotti Andrea , Trusolino Livio , Matito Judit , Vivancos Ana , Chicote Irene , Palmer Héctor G. , Tabernero Josep , Scaltriti Maurizio , Baselga José , Serra Violeta
Published: April 2023

Supplementary Figure and Table Legends. The text describes the panels and tables included as Supplementary Figure and Table Legends
Supplementary figures S1-4 from Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models
Authors: Liu Yan , Hawkins Oriana E. , Vilgelm Anna E. , Pawlikowski Jeffrey S. , Ecsedy Jeffrey A. , Sosman Jeffrey A. , Kelley Mark C. , Richmond Ann
Published: April 2023

Supplementary figures S1-4. Fig. S1: Cells were treated with MLN8237 (1µM) for five days. Real-Time PCR was performed for senescence markers as indicated. Fig. S2: Cells were treated with MLN8237 for different time points followed by SA-β-Gal staining. The percentage of SA-β-Gal positive cells is shown. Fig. S3: Cells were treated with increased concentration of the DR5 small-molecule activator and DMSO or MLN8237 for five days, followed by crystal violet staining. Fig. S4: The tissue slides from the PDX experiment (IgG, DR5 Ab, MLN8237 or MLN8237 + DR5 Ab treatment)were stained for GLB1 (Green) and cleaved caspase 3 (Red).
Supplementary methods and legends from Methionine Deprivation Induces a Targetable Vulnerability in Triple-Negative Breast Cancer Cells by Enhancing TRAIL Receptor-2 Expression
Authors: Strekalova Elena , Malin Dmitry , Good David M. , Cryns Vincent L.
Published: April 2023

Supplementary methods and legends
Supplementary Expression Data from Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer
Authors: Kummar Shivaani , Oza Amit M. , Fleming Gini F. , Sullivan Daniel M. , Gandara David R. , Naughton Michael J. , Villalona-Calero Miguel A. , Morgan Robert J. , Szabo Peter M. , Youn Ahrim , Chen Alice P. , Ji Jiuping , Allen Deborah E. , Lih Chih-Jian , Mehaffey Michele G. , Walsh William D. , McGregor Paul M. , Steinberg Seth M. , Williams P. Mickey , Kinders Robert J. , Conley Barbara A. , Simon Richard M. , Doroshow James H.
Published: April 2023

Supplementary Expression Data. Individual expression values for all 211 genes interrogated in the tumor tissue of 55 patients.
Figure S2 from Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer
Authors: Kummar Shivaani , Oza Amit M. , Fleming Gini F. , Sullivan Daniel M. , Gandara David R. , Naughton Michael J. , Villalona-Calero Miguel A. , Morgan Robert J. , Szabo Peter M. , Youn Ahrim , Chen Alice P. , Ji Jiuping , Allen Deborah E. , Lih Chih-Jian , Mehaffey Michele G. , Walsh William D. , McGregor Paul M. , Steinberg Seth M. , Williams P. Mickey , Kinders Robert J. , Conley Barbara A. , Simon Richard M. , Doroshow James H.
Published: April 2023

Supplemental Figure S2. PAR levels in patient PBMC samples. Data shown in dark red are from patients who reported deleterious BRCA mutations, data shown in dark blue are from patients reporting wildtype BRCA status, and data in grey are from patients with unknown BRCA status.
Supplementary information from Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance)
Authors: Magbanua Mark Jesus M. , Rugo Hope S. , Wolf Denise M. , Hauranieh Louai , Roy Ritu , Pendyala Praveen , Sosa Eduardo V. , Scott Janet H. , Lee Jin Sun , Pitcher Brandelyn , Hyslop Terry , Barry William T. , Isakoff Steven J. , Dickler Maura , van't Veer Laura , Park John W.
Published: April 2023

Supplementary information Supplementary Table 1. Patients and samples Supplementary Table 2. Gene panel for expression analysis Supplementary Table 3. List of recurrent gene copy number aberrations in circulating tumor cells from 49 patients Supplementary Table 4. Association between CTC phenotypes and patient outcome. *p values in bold are statistically significant; - not analyzed.
Supplementary Table S3 from Prognostic and Chemotherapy Predictive Value of Gene-Expression Phenotypes in Primary Lung Adenocarcinoma
Authors: Ringnér Markus , Jönsson Göran , Staaf Johan
Published: April 2023

Supplementary Table S3. Table providing detailed survival results for univariate and multivariate analyses of association of subtype classification with distant metastasis-free survival.
Supplementary methods from Stem Cells Increase in Numbers in Perinecrotic Areas in Human Renal Cancer
Authors: Varna Mariana , Gapihan Guillaume , Feugeas Jean-Paul , Ratajczak Philippe , Tan Sophie , Ferreira Irmine , Leboeuf Christophe , Setterblad Niclas , Duval Arnaud , Verine Jérôme , Germain Stéphane , Mongiat-Artus Pierre , Janin Anne , Bousquet Guilhem
Published: April 2023

supplementary methods
Supplementary Figure Legends from Prognostic and Chemotherapy Predictive Value of Gene-Expression Phenotypes in Primary Lung Adenocarcinoma
Authors: Ringnér Markus , Jönsson Göran , Staaf Johan
Published: April 2023

Figure legends for supplementary figures.
Figure S3 from Stem Cells Increase in Numbers in Perinecrotic Areas in Human Renal Cancer
Authors: Varna Mariana , Gapihan Guillaume , Feugeas Jean-Paul , Ratajczak Philippe , Tan Sophie , Ferreira Irmine , Leboeuf Christophe , Setterblad Niclas , Duval Arnaud , Verine Jérôme , Germain Stéphane , Mongiat-Artus Pierre , Janin Anne , Bousquet Guilhem
Published: April 2023

Figure S3. Distribution of pimonidazole-stained hypoxic cells in xenografted human RCC
Supplementary Tables 3, 5, 6 and 7 from CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients
Authors: Birzele Fabian , Voss Edgar , Nopora Adam , Honold Konrad , Heil Florian , Lohmann Sabine , Verheul Henk , Le Tourneau Christophe , Delord Jean-Pierre , van Herpen Carla , Mahalingam Devalingam , Coveler Andrew L. , Meresse Valerie , Weigand Stefan , Runza Valeria , Cannarile Michael
Published: April 2023

Supplementary Tables 3, 5, 6 and 7. Supplementary Table 3: Contains the results of the differential gene expression analysis between CD44s HEK and native HEK cells (log ratios on the gene level and FDR corrected p-values) Supplementary Table 5: Contains the results of differential gene expression analysis between a subgroup of TCGA UECE patients expressing either CD44s or CD44v as major isoform (log ratio and FDR corrected p-values) Supplementary Table 6: Contains the results of differential gene expression analysis between a subgroup of TCGA BRCA patients expressing either CD44s or CD44v as major isoform (log ratio and FDR corrected p-values) Supplementary Table 7: Contains the results of differential gene expression analysis between a subgroup of TCGA LUSC patients expressing either CD44s or CD44v as major isoform (log ratio and FDR corrected p-values)
Supplementary Figures 1 - 4 from mTOR Inhibitors Induce Cell-Cycle Arrest and Inhibit Tumor Growth in Epstein–Barr Virus–Associated T and Natural Killer Cell Lymphoma Cells
Authors: Kawada Jun-ichi , Ito Yoshinori , Iwata Seiko , Suzuki Michio , Kawano Yoshihiko , Kanazawa Tetsuhiro , Siddiquey Mohammed Nure Alam , Kimura Hiroshi
Published: April 2023

Supplementary Figure 1. Densitometoric analysis of immunoblotting. Supplementary Figure 2. Rapamycin inhibits proliferation of T and NK cell lines. Supplementary Figure 3. CCI-779 induces inhibition of cell proliferation by G1 cell cycle arrest in Epstein-Barr virus (EBV)-positive T and NK cell lines. Supplementary Figure 4. CCI-779 inhibits tumor growth and proliferation in the murine xenograft model. CCI-779 inhibits growth of subcutaneous xenograft tumors in NOG mice.
Supplementary Methods, Figures (1-6) and Tables (1, 2 and 4) from CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients
Authors: Birzele Fabian , Voss Edgar , Nopora Adam , Honold Konrad , Heil Florian , Lohmann Sabine , Verheul Henk , Le Tourneau Christophe , Delord Jean-Pierre , van Herpen Carla , Mahalingam Devalingam , Coveler Andrew L. , Meresse Valerie , Weigand Stefan , Runza Valeria , Cannarile Michael
Published: April 2023

Supplementary Methods, Figures (1-6) and Tables (1, 2 and 4). Supplementary Figure 1: Shows how RG7356 blocks binding of CD44-Fc to HA in a concentration dependent manner for two fixed CD44-Fc concentrations. Supplementary Figure 2: Shows hyaluronic acid levels in cell lysate and supernatant in 12 HEK293 clones transfected with CD44s. Clone 4 was selected for further experiments Supplementary Figure 3: Absolute signal of CD44s expression based on RNASeq data compared to CD44s levels measured by Westernblot (IM7 antibody). Supplementary Figure 4: Absolute signal of CD44v expression based on RNASeq data compared to the CD44v levels measured by Westernblot (BMSv6 antibody). Supplementary Figure 5: Western Blots of the 36 cancer cell lines used for Xenograft models using either IM7 or BMSv6 antibodies. Supplementary Figure 6: Western Blot analysis of CD44 isoform status in samples from 9 human tumor xenograft models using either IM7 or BMSv6 antibodies. Supplementary Table 1: Details for all xenograft models: cell line name, source, %TGI, CD44 isoform status, growth medium, inoculation site, treatment schedule and dose Supplementary Table 2: Cell line name, source, CD44 isoform status as well as hyaluronic acid levels in 36 human solid tumor cell lines. Supplementary Table 4: Number of genes found to be differentially regulated in BRCA, LUSC and UCEC cancer patients available in TCGA either expressing CD44s or CD44v.
Supplemental Figure Legend from mTOR Inhibitors Induce Cell-Cycle Arrest and Inhibit Tumor Growth in Epstein–Barr Virus–Associated T and Natural Killer Cell Lymphoma Cells
Authors: Kawada Jun-ichi , Ito Yoshinori , Iwata Seiko , Suzuki Michio , Kawano Yoshihiko , Kanazawa Tetsuhiro , Siddiquey Mohammed Nure Alam , Kimura Hiroshi
Published: April 2023

Supplemental Figure Legend from mTOR Inhibitors Induce Cell-Cycle Arrest and Inhibit Tumor Growth in Epstein–Barr Virus–Associated T and Natural Killer Cell Lymphoma Cells
Supplemental Figure 1 from Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma
Authors: Calles Antonio , Sholl Lynette M. , Rodig Scott J. , Pelton Ashley K. , Hornick Jason L. , Butaney Mohit , Lydon Christine , Dahlberg Suzanne E. , Oxnard Geoffrey R. , Jackman David M. , Jänne Pasi A.
Published: April 2023

Supplemental Figure 1. A, OS in stage IV KRAS-mutant NSCLC according to KRAS tranversion or transition mutations and LKB1 status. B, OS by different KRAS mutations (G12C vs. G12D)
Supplemental Figure 2 from Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma
Authors: Vassilakopoulou Maria , Avgeris Margaritis , Velcheti Vamsidhar , Kotoula Vassiliki , Rampias Theodore , Chatzopoulos Kyriakos , Perisanidis Christos , Kontos Christos K. , Giotakis Aris I. , Scorilas Andreas , Rimm David , Sasaki Clarence , Fountzilas George , Psyrri Amanda
Published: April 2023

Supplemental Figure 2. Analysis of laryngeal SCC patients' survival according to PD-L1 mRNA expression. Kaplan-Meier curves for the analysis of the prognostic significance of PD-L1 mRNA expression in (a, b) FFPE specimens (cohort I) for the (a) disease-free survival (DFS) and (b) overall survival (OS), and in (c, d) tissue specimens (cohort II) for the (c) DFS and (d) OS. The p values calculated by log-rank test.
Supplementary Figure 4 from Stool Bacteriomic Profiling in Patients with Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor–Tyrosine Kinase Inhibitors
Authors: Pal Sumanta K. , Li Sierra M. , Wu Xiwei , Qin Hanjun , Kortylewski Marcin , Hsu JoAnn , Carmichael Courtney , Frankel Paul
Published: April 2023

Supplementary Figure 4. Species belongs to genera Bacteroides and Prevotella are the driving factors for clustering. Species "Bacteroides, s__" is an unclassified species under genus Bacteroides. Species Copri belongs to genus Prevotella
Supplementary Figures 1 - 3 from Inhibition of Tumor-Derived Prostaglandin-E2 Blocks the Induction of Myeloid-Derived Suppressor Cells and Recovers Natural Killer Cell Activity
Authors: Mao Yumeng , Sarhan Dhifaf , Steven André , Seliger Barbara , Kiessling Rolf , Lundqvist Andreas
Published: April 2023

PDF file - 252K, Figure S1. HLA-DR+ cells do not inhibit NK cells. Figure S2. PGE2 induces suppressive functions on monocytes. Figure S3. COX-2 silencing of tumor cells reduces immune suppression in mice.
Supplementary Figure Legends from Inhibition of Tumor-Derived Prostaglandin-E2 Blocks the Induction of Myeloid-Derived Suppressor Cells and Recovers Natural Killer Cell Activity
Authors: Mao Yumeng , Sarhan Dhifaf , Steven André , Seliger Barbara , Kiessling Rolf , Lundqvist Andreas
Published: April 2023

PDF file - 93K
Supplementary Figure 1 from Stool Bacteriomic Profiling in Patients with Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor–Tyrosine Kinase Inhibitors
Authors: Pal Sumanta K. , Li Sierra M. , Wu Xiwei , Qin Hanjun , Kortylewski Marcin , Hsu JoAnn , Carmichael Courtney , Frankel Paul
Published: April 2023

Supplementary Figure 1. Simpson index plotted against (a) age, (b) diarrhea status, (c) first line therapy vs others and (d) sunitinib vs other systemic treatment
Supplementary Appendix 1 from Stool Bacteriomic Profiling in Patients with Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor–Tyrosine Kinase Inhibitors
Authors: Pal Sumanta K. , Li Sierra M. , Wu Xiwei , Qin Hanjun , Kortylewski Marcin , Hsu JoAnn , Carmichael Courtney , Frankel Paul
Published: April 2023

Supplementary Appendix 1. Details of OTU selection and calculation of alpha and beta diversity indices
Supplementary Figure S2 from Deoxycytidine Kinase Expression Underpins Response to Gemcitabine in Bladder Cancer
Authors: Kerr Martin , Scott Helen E. , Groselj Blaz , Stratford Michael R.L. , Karaszi Katalin , Sharma Naomi L. , Kiltie Anne E.
Published: April 2023

Supplementary Figure S2. A) Quantification of gemcitabine metabolising proteins in four bladder cancer cell lines. Densitometry of bands was measured using the Licor Odyssey system and normalised to loading control (ÃŽÂ² tubulin). In order to make accurate inter-blot comparisons, protein levels were then normalised to the RT112 cell line. B) Quantification of siRNA knockdown in RT112 cells. All samples were normalised against ÃŽÂ² tubulin. Knockdown levels were quantified as a percentage of protein remaining compared to levels of nonsilencing control siRNA treated samples.
Supplementary Figure S1 from Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer
Authors: Wouters Maartje C.A. , Komdeur Fenne L. , Workel Hagma H. , Klip Harry G. , Plat Annechien , Kooi Neeltje M. , Wisman G. Bea A. , Mourits Marian J.E. , Arts Henriette J.G. , Oonk Maaike H.M. , Yigit Refika , de Jong Steven , Melief Cornelis J.M. , Hollema Harry , Duiker Evelien W. , Daemen Toos , de Bruyn Marco , Nijman Hans W.
Published: April 2023

Disease-specific survival (DSS) analyses by Kaplan Meier method of cohort treated with primary surgery (PS) and cohort treated with neo-adjuvant chemotherapy (NACT). A) DSS depicted for patients in PS cohort split on surgical outcome. B) Age is a predictor for survival in the PS cohort. C) Prognostic effect of surgical outcome in the NACT cohort. D) Age is not a predictor of survival in the NACT cohort.
supplemental figure legend from Larger Size of Donor Alloreactive NK Cell Repertoire Correlates with Better Response to NK Cell Immunotherapy in Elderly Acute Myeloid Leukemia Patients
Authors: Curti Antonio , Ruggeri Loredana , Parisi Sarah , Bontadini Andrea , Dan Elisa , Motta Maria Rosa , Rizzi Simonetta , Trabanelli Sara , Ocadlikova Darina , Lecciso Mariangela , Giudice Valeria , Fruet Fiorenza , Urbani Elena , Papayannidis Cristina , Martinelli Giovanni , Bandini Giuseppe , Bonifazi Francesca , Lewis Russell E. , Cavo Michele , Velardi Andrea , Lemoli Roberto M.
Published: April 2023

supplemental figure legend
Supplementary figure S6 from EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer
Authors: Dunne Philip D. , Dasgupta Sonali , Blayney Jaine K. , McArt Darragh G. , Redmond Keara L. , Weir Jessica-Anne , Bradley Conor A. , Sasazuki Takehiko , Shirasawa Senji , Wang Tingting , Srivastava Supriya , Ong Chee Wee , Arthur Ken , Salto-Tellez Manuel , Wilson Richard H. , Johnston Patrick G. , Van Schaeybroeck Sandra
Published: April 2023

The role of microenvironment-derived ligands in regulating EphA2 expression levels.
Supplementary Tables S1 and S2 from Larger Size of Donor Alloreactive NK Cell Repertoire Correlates with Better Response to NK Cell Immunotherapy in Elderly Acute Myeloid Leukemia Patients
Authors: Curti Antonio , Ruggeri Loredana , Parisi Sarah , Bontadini Andrea , Dan Elisa , Motta Maria Rosa , Rizzi Simonetta , Trabanelli Sara , Ocadlikova Darina , Lecciso Mariangela , Giudice Valeria , Fruet Fiorenza , Urbani Elena , Papayannidis Cristina , Martinelli Giovanni , Bandini Giuseppe , Bonifazi Francesca , Lewis Russell E. , Cavo Michele , Velardi Andrea , Lemoli Roberto M.
Published: April 2023

Table S1. Percentage and absolute number of alloreactive NK cells in responders (A) and non-responders (B) Table S2. Description of cell processing results in responders (A) and non-responders (B)
Supplementary figure S5 from EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer
Authors: Dunne Philip D. , Dasgupta Sonali , Blayney Jaine K. , McArt Darragh G. , Redmond Keara L. , Weir Jessica-Anne , Bradley Conor A. , Sasazuki Takehiko , Shirasawa Senji , Wang Tingting , Srivastava Supriya , Ong Chee Wee , Arthur Ken , Salto-Tellez Manuel , Wilson Richard H. , Johnston Patrick G. , Van Schaeybroeck Sandra
Published: April 2023

EphA2 and overall survival in stage II and III CRC.
Supplementary figure S1 from EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer
Authors: Dunne Philip D. , Dasgupta Sonali , Blayney Jaine K. , McArt Darragh G. , Redmond Keara L. , Weir Jessica-Anne , Bradley Conor A. , Sasazuki Takehiko , Shirasawa Senji , Wang Tingting , Srivastava Supriya , Ong Chee Wee , Arthur Ken , Salto-Tellez Manuel , Wilson Richard H. , Johnston Patrick G. , Van Schaeybroeck Sandra
Published: April 2023

EphA2 and EFNA1 expression levels in colorectal cancer cells.
Supplementary Figure 2 from Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell–Mediated Tumor Control in the Genital Tract
Authors: Sun Yun-Yan , Peng Shiwen , Han Liping , Qiu Jin , Song Liwen , Tsai Yachea , Yang Benjamin , Roden Richard B.S. , Trimble Cornelia L. , Hung Chien-Fu , Wu T.-C.
Published: April 2023

Characterization of MAdCAM-1 expression in cervicovaginal tissue after vaccination
Supplementary Table 1 from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235
Authors: Hall Connor P. , Reynolds C. Patrick , Kang Min H.
Published: April 2023

Supplementary Table 1. Karyotype and PTEN mutational status and karyotype of B- and T-acute lymphoblastic leukemia/lymphoma cell lines.
Supplemental Figure 2 from The NEDD8-Activating Enzyme Inhibitor MLN4924 Disrupts Nucleotide Metabolism and Augments the Efficacy of Cytarabine
Authors: Nawrocki Steffan T. , Kelly Kevin R. , Smith Peter G. , Keaton Mignon , Carraway Hetty , Sekeres Mikkael A. , Maciejewski Jaroslaw P. , Carew Jennifer S.
Published: April 2023

Supplemental Figure 2. Schematic of purine nucleotide metabolism pathway.
Supplementary Figure 6 from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235
Authors: Hall Connor P. , Reynolds C. Patrick , Kang Min H.
Published: April 2023

Suppl Fig 6. Mechanism of synergy of BEZ235 plus dexamethasone.
Supplementary Figure 1 from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235
Authors: Hall Connor P. , Reynolds C. Patrick , Kang Min H.
Published: April 2023

Suppl Fig 1. GC Receptor expression and functionality in T- and B-ALL cell lines.
Suppl Fig 2 from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235
Authors: Hall Connor P. , Reynolds C. Patrick , Kang Min H.
Published: April 2023

Suppl Fig 2. BEZ235, Dexamethasone, and the combination effect on cell cycle.
Figure S1 from Glycogen Synthase Kinase 3 Beta Predicts Survival in Resected Adenocarcinoma of the Pancreas
Authors: Ben-Josef Edgar , George Asha , Regine William F. , Abrams Ross , Morgan Meredith , Thomas Dafydd , Schaefer Paul L. , DiPetrillo Thomas A. , Fromm Mitchel , Small William , Narayan Samir , Winter Kathryn , Griffith Kent A. , Guha Chandan , Williams Terence M.
Published: April 2023

Figure S1. Exploratory analysis
Supplementary Legends_qc from Functional Subclone Profiling for Prediction of Treatment-Induced Intratumor Population Shifts and Discovery of Rational Drug Combinations in Human Glioblastoma
Authors: Reinartz Roman , Wang Shanshan , Kebir Sied , Silver Daniel J. , Wieland Anja , Zheng Tong , Küpper Marius , Rauschenbach Laurèl , Fimmers Rolf , Shepherd Timothy M. , Trageser Daniel , Till Andreas , Schäfer Niklas , Glas Martin , Hillmer Axel M. , Cichon Sven , Smith Amy A. , Pietsch Torsten , Liu Ying , Reynolds Brent A. , Yachnis Anthony , Pincus David W. , Simon Matthias , Brüstle Oliver , Steindler Dennis A. , Scheffler Björn
Published: April 2023

Legends for Supplementary Figs. S1-S8 and Supplementary Tables
Conflict of Interest Form Aldinucci D from Preclinical Activity of the Liposomal Cisplatin Lipoplatin in Ovarian Cancer
Authors: Casagrande Naike , Celegato Marta , Borghese Cinzia , Mongiat Maurizio , Colombatti Alfonso , Aldinucci Donatella
Published: April 2023

Conflict of Interest Form
Supplementary Figure S1qc from Functional Subclone Profiling for Prediction of Treatment-Induced Intratumor Population Shifts and Discovery of Rational Drug Combinations in Human Glioblastoma
Authors: Reinartz Roman , Wang Shanshan , Kebir Sied , Silver Daniel J. , Wieland Anja , Zheng Tong , Küpper Marius , Rauschenbach Laurèl , Fimmers Rolf , Shepherd Timothy M. , Trageser Daniel , Till Andreas , Schäfer Niklas , Glas Martin , Hillmer Axel M. , Cichon Sven , Smith Amy A. , Pietsch Torsten , Liu Ying , Reynolds Brent A. , Yachnis Anthony , Pincus David W. , Simon Matthias , Brüstle Oliver , Steindler Dennis A. , Scheffler Björn
Published: April 2023

Box plots showing IC50 values from pilot data pharmacological profiling.
Supplemental Figure 6 from Inhibition of the EGFR/STAT3/CEBPD Axis Reverses Cisplatin Cross-resistance with Paclitaxel in the Urothelial Carcinoma of the Urinary Bladder
Authors: Wang Wei-Jan , Li Chien-Feng , Chu Yu-Yi , Wang Yu-Hui , Hour Tzyh-Chyuan , Yen Chia-Jui , Chang Wen-Chang , Wang Ju-Ming
Published: April 2023

Attenuated pSTAT3, CEBPD, ABCB1 and ABCC2 mRNA levels are observed in CDDP-resistant NTUB1/P xenografted NOD/SCID mice. A and B, Following 3 weeks of drug treatment, all animals were sacrificed, and their tumors were collected for protein and mRNA analysis. Protein samples were employed for Western blot analysis by using specific antibodies. The following data present changes in pSTAT3, CEBPD, and ABCB1 levels in NTUB1/P-xenografted NOD/SCID mice treated with CDDP and gefitinib or with CDDP and S3I-201. qPCR assays were performed using the total RNA harvested from tumor samples. In this figure, *** denotes a significant difference (P < 0.001). B, evaluation of body weight of experimental mice used in Fig. 5. CTL: control.
Table S2 from Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma
Authors: Krytska Kateryna , Ryles Hannah T. , Sano Renata , Raman Pichai , Infarinato Nicole R. , Hansel Theodore D. , Makena Monish R. , Song Michael M. , Reynolds C. Patrick , Mossé Yael P.
Published: April 2023

Determination of combinations indexes (CI) in crizotinib- and topotecan-treated neuroblastoma cells harboring varying ALK and TP53 genotypes.
Figure S5.A from The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1)
Authors: Vena Francesca , Li Causi Eleonora , Rodriguez-Justo Manuel , Goodstal Samantha , Hagemann Thorsten , Hartley John A. , Hochhauser Daniel
Published: April 2023

Figure S5.A. Inhibition of tumor growth in mice treated with 15mg/kg pimasertib plus 80mg/kg gemcitabine.
Figure S2 from Identification of a Novel, EBV-Based Antibody Risk Stratification Signature for Early Detection of Nasopharyngeal Carcinoma in Taiwan
Authors: Coghill Anna E. , Pfeiffer Ruth M. , Proietti Carla , Hsu Wan-Lun , Chien Yin-Chu , Lekieffre Lea , Krause Lutz , Teng Andy , Pablo Jocelyn , Yu Kelly J. , Lou Pei-Jen , Wang Cheng-Ping , Liu Zhiwei , Chen Chien-Jen , Middeldorp Jaap , Mulvenna Jason , Bethony Jeff , Hildesheim Allan , Doolan Denise L.
Published: April 2023

Coefficient of variation by study and antibody.
Figure S2.C from The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1)
Authors: Vena Francesca , Li Causi Eleonora , Rodriguez-Justo Manuel , Goodstal Samantha , Hagemann Thorsten , Hartley John A. , Hochhauser Daniel
Published: April 2023

Figure S2.C. Pimasertib effect on RRM1 protein expression in human pancreatic cancer cell lines.
Figure S1.B from The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1)
Authors: Vena Francesca , Li Causi Eleonora , Rodriguez-Justo Manuel , Goodstal Samantha , Hagemann Thorsten , Hartley John A. , Hochhauser Daniel
Published: April 2023

Figure S1.B. Apoptotic effect of simultaneous administration of pimasertib with gemcitabine.
Supplementary Data 6 from Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration
Authors: Frenel Jean Sebastien , Carreira Suzanne , Goodall Jane , Roda Desam , Perez-Lopez Raquel , Tunariu Nina , Riisnaes Ruth , Miranda Susana , Figueiredo Ines , Nava-Rodrigues Daniel , Smith Alan , Leux Christophe , Garcia-Murillas Isaac , Ferraldeschi Roberta , Lorente David , Mateo Joaquin , Ong Michael , Yap Timothy A. , Banerji Udai , Gasi Tandefelt Delila , Turner Nick , Attard Gerhardt , de Bono Johann S.
Published: April 2023

Supplementary Data 6: Monitoring of somatic genomic alterations in plasma during targeted therapy. Allele frequencies (AF) of identified mutations are represented on the left Y-axis while the sum of the target lesions on the CT scan, are represented on the right Y-axis.
Supplementary Figure Legends from Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein–Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression
Authors: Jones Richard J. , Iempridee Tawin , Wang Xiaobin , Lee Hans C. , Mertz Janet E. , Kenney Shannon C. , Lin Heather C. , Baladandayuthapani Veerabhadran , Dawson Christopher W. , Shah Jatin J. , Weber Donna M. , Orlowski Robert Z.
Published: April 2023

Contains the text for the supplementary figures.
Comparison of p values of tumor volume between different treatment groups at different time points. from Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein–Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression
Authors: Jones Richard J. , Iempridee Tawin , Wang Xiaobin , Lee Hans C. , Mertz Janet E. , Kenney Shannon C. , Lin Heather C. , Baladandayuthapani Veerabhadran , Dawson Christopher W. , Shah Jatin J. , Weber Donna M. , Orlowski Robert Z.
Published: April 2023

P values of mouse tumor volumes over time
Supplementary Figure S6 from Deregulation of the PP2A Inhibitor SET Shows Promising Therapeutic Implications and Determines Poor Clinical Outcome in Patients with Metastatic Colorectal Cancer
Authors: Cristóbal Ion , Rincón Raúl , Manso Rebeca , Caramés Cristina , Zazo Sandra , Madoz-Gúrpide Juan , Rojo Federico , García-Foncillas Jesús
Published: April 2023

Supplementary Figure S6. (A) Kaplan-Meier analyses of overall and progression-free survival and in the subgroups of patients with KRAS wild type (N = 136) and KRAS mutated (N = 102). (B) Predictive value of response to treatment by SET deregulation in those patients who received oxaliplatin-based chemotherapy (N= 101).
Supplementary Figure S4 from Deregulation of the PP2A Inhibitor SET Shows Promising Therapeutic Implications and Determines Poor Clinical Outcome in Patients with Metastatic Colorectal Cancer
Authors: Cristóbal Ion , Rincón Raúl , Manso Rebeca , Caramés Cristina , Zazo Sandra , Madoz-Gúrpide Juan , Rojo Federico , García-Foncillas Jesús
Published: April 2023

Supplementary Figure S4. Effects of FTY720 in SW480, HT-29 and LS513 cells ectopically expressing SET and treated with 5-FU alone or combined with oxaliplatin.
Supplemental Figure 2. from Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities
Authors: Eaton Anne , Iasonos Alexia , Gounder Mrinal M. , Pamer Erika G. , Drilon Alexander , Vulih Diana , Smith Gary L. , Ivy S. Percy , Spriggs David R. , Hyman David M.
Published: April 2023

Histograms of physician attribution (5-tier scale) of all grade {greater than or equal to}3 toxicities by toxicity category. On the attribution scale (x axis), 1 represents 'unrelated', 2 represents 'unlikely related', 3 represents 'possibly related', 4 represents 'probably related', and 5 represents 'definitely related'.
Supplementary Table 3 from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer
Authors: Wang Rui , Wang Lei , Li Yuan , Hu Haichuan , Shen Lei , Shen Xuxia , Pan Yunjian , Ye Ting , Zhang Yang , Luo Xiaoyang , Zhang Yiliang , Pan Bin , Li Bin , Li Hang , Zhang Jie , Pao William , Ji Hongbin , Sun Yihua , Chen Haiquan
Published: April 2023

Clinicopathologic Characteristics in NSCLC Patients with FGFR, ALK, RET and ROS1 fusions
Supplemental Figure 5 from SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer
Authors: Zhang Xiaotun , Coleman Ilsa M. , Brown Lisha G. , True Lawrence D. , Kollath Lori , Lucas Jared M. , Lam Hung-Ming , Dumpit Ruth , Corey Eva , Chéry Lisly , Lakely Bryce , Higano Celestia S. , Montgomery Bruce , Roudier Martine , Lange Paul H. , Nelson Peter S. , Vessella Robert L. , Morrissey Colm
Published: April 2023

AgilentTM oligo array expression analysis of the top and bottom 20 neuroendocrine/neuronal-associated genes in 24 LuCaP xenograft lines. LuCaP 49, 93, 145.1 and 145.2 are all classed as AR- NE xenografts. Mean-centered ratios of genes are colored according to scale (Supplemental Figure 2).
Supplementary Table 1 from Circulating Tumor Cell Analysis in Metastatic Triple-Negative Breast Cancers
Authors: Magbanua Mark Jesus M. , Carey Lisa A. , DeLuca Amy , Hwang Jimmy , Scott Janet H. , Rimawi Mothaffar F. , Mayer Erica L. , Marcom P. Kelly , Liu Minetta C. , Esteva Francisco J. , Park John W. , Rugo Hope S.
Published: April 2023

Supplementary Table 1. REMARK flow diagram of patients and sample collection and processing for each enumeration method (CellSearch and IE/FC). Blood samples from 102 patients with metastatic triple-negative breast cancer were collected at baseline and 7-14days after initiation of treatment. Circulating tumor cells in patients' blood from the same draw were contemporaneously enumerated by CellSearch and IE/FC.
Supplementary Figure Legends from Circulating Tumor Cell Analysis in Metastatic Triple-Negative Breast Cancers
Authors: Magbanua Mark Jesus M. , Carey Lisa A. , DeLuca Amy , Hwang Jimmy , Scott Janet H. , Rimawi Mothaffar F. , Mayer Erica L. , Marcom P. Kelly , Liu Minetta C. , Esteva Francisco J. , Park John W. , Rugo Hope S.
Published: April 2023

Supplementary Figure Legends. REMARK flow diagram
Supplementary Table S1 from Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer
Authors: Ring Alistair , Wheatley Duncan , Hatcher Helen , Laing Robert , Plummer Ruth , Uttenreuther-Fischer Martina , Temple Graham , Pelling Katy , Schnell David
Published: April 2023

Supplementary Table S1. Best overall response (RECIST version 1.1)
Supplementary Table 2 from Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like Subsets
Authors: Rekhtman Natasha , Pietanza Maria C. , Hellmann Matthew D. , Naidoo Jarushka , Arora Arshi , Won Helen , Halpenny Darragh F. , Wang Hangjun , Tian Shaozhou K. , Litvak Anya M. , Paik Paul K. , Drilon Alexander E. , Socci Nicholas , Poirier John T. , Shen Ronglai , Berger Michael F. , Moreira Andre L. , Travis William D. , Rudin Charles M. , Ladanyi Marc
Published: April 2023

Supplementary Table 2: Immunohistochemical antibodies and protocols
Supplementary Figure 3. Lenvatanib inhibits cell invasion and colony formation in prostate cancer. from RET Signaling in Prostate Cancer
Authors: Ban Kechen , Feng Shu , Shao Longjiang , Ittmann Michael
Published: April 2023

Effect of lenvatinib at 100 or 500nM on invasion (A) and soft agar colony formation (B). The p-values for significant differences by t-test are shown.
Supplementary Tables S1-5 from Gene Expression Signatures and Immunohistochemical Subtypes Add Prognostic Value to Each Other in Breast Cancer Cohorts
Authors: Lundberg Arian , Lindström Linda S. , Harrell J. Chuck , Falato Claudette , Carlson Joseph W. , Wright Paul K. , Foukakis Theodoros , Perou Charles M. , Czene Kamila , Bergh Jonas , Tobin Nicholas P.
Published: April 2023

Supplementary table S1. Cell cycle genes Supplementary table S2. Cross-table of concordance between Ki67 immunohistochemical staining and gene expression signature classifications in Cohorts 1 and 2 Supplementary table S3. Clinico-pathological characteristics of patient subgroups in cohort 1 Supplementary table S4. Change in C-index when adding gene expression signatures to Ki67/IHC for All, ER+/LN-, ER+/LN-, ER- patients in Cohorts 1 and 2. Supplementary Table S5. Clinico-pathological characteristics of patient subgroups in cohort 2
Supplementary Tables 1 and 2 from Neural Stem Cell–Based Anticancer Gene Therapy: A First-in-Human Study in Recurrent High-Grade Glioma Patients
Authors: Portnow Jana , Synold Timothy W. , Badie Behnam , Tirughana Revathiswari , Lacey Simon F. , D'Apuzzo Massimo , Metz Marianne Z. , Najbauer Joseph , Bedell Victoria , Vo Tien , Gutova Margarita , Frankel Paul , Chen Mike , Aboody Karen S.
Published: April 2023

Supplementary Table 1: A standard 3 + 3 dose escalation design (19) was used to investigate 3 dose levels of CD-NSCs and 5-FC. Supplementary Table 2: Characteristics of the 15 patients who received study treatment.
Supplementary Figure 7 from Potent Anti-leukemia Activities of Chimeric Antigen Receptor–Modified T Cells against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia
Authors: Hu Yongxian , Wu Zhao , Luo Yi , Shi Jimin , Yu Jian , Pu Chengfei , Liang Zuyu , Wei Guoqing , Cui Qu , Sun Jie , Jiang Jing , Xie Jue , Tan Yamin , Ni Wanmao , Tu Jifang , Wang Jinping , Jin Aiyun , Zhang Hao , Cai Zhen , Xiao Lei , Huang He
Published: April 2023

CRS complication after CART19 therapy. A, the peak serum concentration of IL-6, IFN-Î³, IL-10, CRP, D-dimer and ferritin of a representative patient (Patient 15) during CRS at the indicated time-points after CART19 infusion are showed. B, D, Peak serum levels of CRP, ferritin and D-dimer in patients who developed grade 3 CRS (n=6) compared with those without CRS or with 1 or 2 CRS (n=10). Data represented the mean{plus minus}SEM. The Mann-Whitney U test was used for statistical analysis. C, Paired measurements of peak serum IL-6, CRP, ferritin and D-dimer showed strong correlations (IL-6 VS CRP, Spearman r=0.617, p=0.014; IL-6 VS ferritin, Spearman r=0.574, p=0.028; IL-6 VS D-dimer, Spearman r=0.789, p<0.01).
Supplementary Figure 4 from Potent Anti-leukemia Activities of Chimeric Antigen Receptor–Modified T Cells against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia
Authors: Hu Yongxian , Wu Zhao , Luo Yi , Shi Jimin , Yu Jian , Pu Chengfei , Liang Zuyu , Wei Guoqing , Cui Qu , Sun Jie , Jiang Jing , Xie Jue , Tan Yamin , Ni Wanmao , Tu Jifang , Wang Jinping , Jin Aiyun , Zhang Hao , Cai Zhen , Xiao Lei , Huang He
Published: April 2023

Comparison of CART19 levels in different groups. A, Levels of CART19 cells in PB were shown as assessed by means of qPCR assay at serial time points before and after infusion of CART19 respectively. B, CAR DNA copies in BM and PB on day 7 to 9 after CART19 infusion were compared. CAR DNA copies in BM (Patient 2, 6, 11, 13) were higher than in PB. C, Paired measurements of CAR DNA copies in BM and PB on day 7 to 9 after CART19 infusion, percentage of leukemia cells after FC chemotherapy shows strong correlations (CAR DNA copies in BM VS in PB, Spearman r=0.956, p<0.001; CAR DNA copies in BM VS percentage of leukemia cells after FC chemotherapy, Spearman r=0.699, p=0.011; CAR DNA copies in BM VS percentage of leukemia cells after FC chemotherapy, Spearman r=0.755, p=0.005). Data for patients 4 and 13 are not included. C, Paired measurements of peak CAR DNA copies in BM or peak CART count after CART19 infusion and infused CART dose shows no correlations (peak CAR DNA copies in BM VS infused CART dose, Spearman r=0.248, p=0.438; peak CART count in PB VS infused CART dose, Spearman r=0.172, p=0.594).
Table S1-S3 from PTEN Is Fundamental for Elimination of Leukemia Stem Cells Mediated by GSK126 Targeting EZH2 in Chronic Myelogenous Leukemia
Authors: Zhou Jingfeng , Nie Danian , Li Juan , Du Xin , Lu Yuhong , Li Yangqiu , Liu Chang , Dai Wei , Wang Yun , Jin Yanli , Pan Jingxuan
Published: April 2023

Table S1 shows the Characteristics of patients with CML; Table S2 shows the sequence of shRNA; Table S3 shows the limiting dilution assay of mouse LT-HSC after shEZH2 treatment
Supplementary Table S2 from Intratumor Heterogeneity Affects Gene Expression Profile Test Prognostic Risk Stratification in Early Breast Cancer
Authors: Gyanchandani Rekha , Lin Yan , Lin Hui-Min , Cooper Kristine , Normolle Daniel P. , Brufsky Adam , Fastuca Michael , Crosson Whitney , Oesterreich Steffi , Davidson Nancy E. , Bhargava Rohit , Dabbs David J. , Lee Adrian V.
Published: April 2023

Immunohistochemical expression levels for ER, PR, HER2 and Ki67
Supplementary Figures from Intratumor Heterogeneity Affects Gene Expression Profile Test Prognostic Risk Stratification in Early Breast Cancer
Authors: Gyanchandani Rekha , Lin Yan , Lin Hui-Min , Cooper Kristine , Normolle Daniel P. , Brufsky Adam , Fastuca Michael , Crosson Whitney , Oesterreich Steffi , Davidson Nancy E. , Bhargava Rohit , Dabbs David J. , Lee Adrian V.
Published: April 2023

Figures S1, S2, S3, S4, S5, and S6
Supplemental Table 4 from Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial
Authors: Mohrbacher Ann M. , Yang Allen S. , Groshen Susan , Kummar Shivaani , Gutierrez Martin E. , Kang Min H. , Tsao-Wei Denice , Reynolds C. Patrick , Newman Edward M. , Maurer Barry J.
Published: April 2023

PK Results for 4-HPR and 4-MPR - AUC Over the 1st 48 Hours
Supplemental Table 3 from Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial
Authors: Mohrbacher Ann M. , Yang Allen S. , Groshen Susan , Kummar Shivaani , Gutierrez Martin E. , Kang Min H. , Tsao-Wei Denice , Reynolds C. Patrick , Newman Edward M. , Maurer Barry J.
Published: April 2023

Summary of Completed Dose Levels